Incidence and risk factors for nevirapine-associated rash
- 12 August 2003
- journal article
- pharmacoepidemiology and-prescription
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 59 (5-6) , 457-462
- https://doi.org/10.1007/s00228-003-0613-3
Abstract
To determine the incidence of rash in HIV-1 infected individuals starting a nevirapine-containing regimen in an unselected outpatient clinic population. Possible risk factors including plasma concentrations of nevirapine were evaluated for their relationship with the occurrence of a rash.Keywords
This publication has 22 references indexed in Scilit:
- Prednisolone does not prevent hypersensitivity reactions in antiretroviral drug regimens containing abacavir with or without nevirapineAIDS, 2001
- Nevirapine and the risk of Stevens–Johnson syndrome or toxic epidermal necrolysisAIDS, 2001
- Female sex and the use of anti-allergic agents increase the risk of developing cutaneous rash associated with nevirapine therapyAIDS, 2001
- Prevention of nevirapine-associated rash.The Lancet, 2001
- Sex Differences in Nevirapine RashClinical Infectious Diseases, 2001
- Adverse effects of antiretroviral therapyThe Lancet, 2000
- Experience with Nevirapine in Previously Treated HIV-1-Infected IndividualsAntiviral Therapy, 2000
- A Randomized, Double-Blind Trial on the Use of a Triple Combination Including Nevirapine, a Nonnucleoside Reverse Transcriptase HIV Inhibitor, in Antiretroviral-Naive Patients With Advanced DiseaseJAIDS Journal of Acquired Immune Deficiency Syndromes, 1999
- Hepatitis B Virus InfectionNew England Journal of Medicine, 1997
- High-Dose Nevirapine: Safety, Pharmacokinetics, And Antiviral Effect In Patients With Human Immunodeficiency Virus InfectionThe Journal of Infectious Diseases, 1995